Q2 2019 Earnings Call
Good morning, ladies and gentlemen, and welcome to the Colfax second quarter 2019 earnings Conference call.
At this time all participants are in a listen only mode.
Later, we will conduct a question and answer session.
And instructions will follow at that time.
If anyone should require assistance during the conference. Please press star zero on your Touchtone telephone.
As a reminder, this conference call is being recorded.
I would like to turn the conference over to your host Mr., Mike sulfur.
Thank you Sam good morning, everyone and thank you for joining us on my second full backs is buying G.
Joining me on the call today are Matt Santos, President and CEO , and Chris Davis, Senior Vice President and CFO .
Our earnings release was issued this morning and is available in the investors section of our website Colfax work Dotcom, we will be using a slide presentation to walk you through today's call, which can also be found on our website.
Both the audio and the slide presentation to this call will be archived on our website later today and will be available until the next quarterly earnings call.
During this call, we'll be making some forward looking statements about our beliefs and estimates regarding future events and results. These forward looking statements are subject to risks and uncertainties, including those set forth in our SEC filings.
Actual results may differ materially from any forward looking statements that we make today. The forward looking statements speak only as of today and we do not assume any obligation or intent to update them, except as required by law.
With respect to any non-GAAP financial measures made during the call today. The accompanying reconciliation information related to those measures can be found in our earnings press release and today's slide presentation now I'd like to turn it over to Matt who will start on slide three.
Thanks, Mike and good morning.
We're pleased to report strong financial performance in the second quarter.
Results were at or ahead of expectations in each of our businesses and we made great progress on transforming our company for a very exciting future.
We remain on track to achieve our 2019 guidance adjusted for the air and gas handling sale, Chris will walk you through the before and after numbers later.
And our first full quarter with the medical medical technology business, we accelerated growth through commercial execution product innovation and improving customer service levels.
We're leaning in hard to complete transformation projects this year to position the business for healthy growth and margin improvement next year.
Our fabrication technology business delivered strong margin improvement and the team had its 10th straight quarter of organic growth in modestly softer than expected, but stable end markets.
The air and gas handling business posted its fourth consecutive quarter of double digit order growth and very strong margin improvements demonstrating the success of our diversification strategy and our operational execution. We continue to expect to complete the divestiture later this year.
Turning to slide four you can see we're making good progress on the DJ Vu integration.
The business achieved organic growth of 3.4% up nicely from the first quarter growth rate and moving toward our medium term goal of 4% to 5%.
The reconstructive product lines again delivered double digit growth this quarter with high teens growth in shoulder.
We also had well above market growth in our knee and hip product lines driven in part by positive surgeon response to our empower Andy as we continue to fill out the product line.
Prevention and rehabilitation product lines made healthy sequential growth improvement in the second quarter and finished flat on a year over year basis.
In addition to the higher number of new product launches. This year, we made substantial progress addressing customer service issues.
We expect cost improvements and seasonally higher Q4 volume to support the second half step up in margins consistent with original guidance.
Slide five provides more details on our progress integrating DJ Io and creating a CBS fueled continuous improvement path.
Our workstreams are on track and I've been really pleased with the level of engagement and energy across the jail team.
We continue to have strong momentum in our reconstructive product lines DJ has a track record of implants innovation and have developed great relationships with key opinion leaders in the orthopedic space. We also have a leading position in the higher growth shoulder implant segment and these strong franchise attributes are adding up to consistent double digit growth. This year, and we see long runway to continue well above market growth in surgical.
Thank you for calling the conferencing Center a conference operator will be with you momentarily.
In a more than 60% reduction in pass through revenue in the second quarter.
Our feeling the difference and we now expect.
And rehabilitation product lines to return to organic growth.
In the second half of the year.
Reimbursement is an area, where we see a big opportunity for CBS impact.
The processes, which are critical to revenue growth and cash flow cycle time, our classic application for lean value stream mapping and transactional process improvement.
In recent months the team has made progress or sorry process and organizational improvements that reduced commercial waste and accelerate collections.
We're gaining traction in this area and see multiyear improvement path that will help both the top and bottom lines.
We continue to be excited about the opportunity for innovation driven growth in DJ show the parts of the business with fresh product lines have strong growth and share gain in other parts of the new products are flowing again, and we see healthy pipelines that we can accelerate with CBS and with a little bit of targeted investment.
Moving to slide six fabrication technology continues to drive higher margins and above market growth.
Margins were up 90 basis points from the prior year period from price productivity and cost reductions.
These up team is executing well both commercially and operationally.
With steel prices easing the benefits of continuous improvement and cost reduction projects are reading through.
The second quarter is seasonally the highest margin quarter of the year and we continue to expect meaningful year over year margin improvement in the second half.
We had second quarter organic growth in most global regions, including the U.S.
Volume was flat with global growth offset by softening in the U.S.
We expect low single digit organic growth in the second half from price with a soft but stable global market picture continue to point to roughly flat volume.
GC Sandvik and our other recent bolt on acquisitions are on track and on slide seven you can see the benefits from this important part of our value creation strategy.
Our disciplined acquisition and integration process is enabling us to quickly generate attractive returns from these complimentary acquisitions.
Starting in 2016, we paid an average multiple of about nine and a half.
We focus our strategic acquisitions.
That we focus on strategic acquisitions that make the business is better and our M&A playbook folks as our teams on key value drivers and supports rapid but thoughtful integration.
With this approach we are on track to reduce the overall acquisition multiple on these deals by more than a third in the first two full years of ownership.
An outstanding example of the value created with bolt on M&A is the GC acquisition that we completed last year in our fabrication technology business.
We expect GDP to grow high single digits. This year due to a combination of exposure to faster growing markets and applications, such as healthcare and science research and leveraging E sobs global channels to grow faster outside of its traditional geographic markets.
It's also accretive to gross margin.
We're also delivering on cost synergies by consolidating existing aesop and GC facilities functions and product lines.
Looking forward GC opens up new growth opportunities organically and through additional M&A into higher growth higher margin applications like specialty gas control and related adjacencies.
Slide eight shows another strong quarter in air and gas handling.
We've had four consecutive quarters of double digit order growth a reflection of improved long cycle market conditions, and the strategic repositioning of the business into faster growth markets.
The substantial margin improvement reflects improvements in commercial processes, a shift to more profitable projects.
And cost reductions as we improve the business for long term success.
This successful trajectory enable us to divest the business for an attractive value and we expect to complete the sale later this year.
Before handing off to Chris I'll wrap up on slide nine as we look ahead to the strengths of our newly reshaped portfolio.
Colfax will head into 2020 with a stronger reshaped portfolio.
We've improved our growth potential.
DGF and Aesop have strong brands and market, leading positions on which to build and grow.
You can see on the pie charts that will be nicely balanced globally with China, well under 10% of our total revenues and we'll also have nice balance across industries with a significant amount of medtech through our orthopedic solutions business.
Innovation matters in these businesses.
With plenty of opportunity to drive differentiation and extend or even redefined the solution set for customers.
Acquisitions can improve our scale and reach and accelerate technology development.
DJ sale gives us a number of exciting new directions in which to pursue M&A.
We've also created a higher margin less cyclical company with better cash flow over 90% of our revenue is now from tens of thousands of recurring customers across the world buying hundreds of run rate products and services with average purchase prices measured in hundreds or thousands of dollars.
This diversification.
Along with the non psych Noncyclical med tech demand and Cvs driven margin improvements position us to generate higher and much more stable free cash flow.
Stronger cash flow lets us invest faster in innovation and acquisitions to compound returns for our shareholders.
Before I hand off to Chris to take you through our results and outlook, let me finish by saying that we are on track for what I expect will be a very successful transformative year for Colfax in 2019, and we are positioned for strong performance in 2020.
Thank you, Matt Slide 10 shows our adjusted results on a fully consolidated basis, which assumes we did not sell out and then gives investors one less view of our performance before turning the page to the continuing operations view, the continuing operations basis excludes the air and gas handling business and assumed interest expense savings from the $1.6 billion of approximate cash proceeds from the divestiture.
We have recast in our quarterly results from the first half of 2018 and 19 into this new continuing operations presentation, and we expect to have the second half of 2018 available to investors this quarter.
On a fully consolidated basis Colfax earned 64 cents in the quarter compared with 61 cents last year, a bit stronger than we expected due to good operating performance and lower interest costs.
On a continuing operations basis year over year results are up sharply due to the DJ oil acquisition and the strong performance of our fab Tech businesses, Matt outlined earlier.
Gross margins are significantly higher based on fab Tech progress and DJ as high Fiftys performance.
Adjusted EBITDA and EBITDA margins landed in a healthy zone and are consistent with our plans for the full year.
Continuing ops EPS was 54 cents in the quarter up sharply from 37 cents in the prior year and included two cents of FX headwind.
We're getting the expected contribution from DJ show net of financing costs, and fab techs growth and margin read through to the bottom line.
Let me walk you through our view for the full year on Slide 11, which includes the original outlook, our continuing operations guidance and a pro forma view.
On an operating basis, there is little that has changed in our continuing operations guidance. We continue to expect each of our businesses to deliver the EBITDA and EBITDA as originally planned for the year and discussed in previous Investor calls.
Our med Tech business is forecasted to achieve the high side of our revenue growth guidance based on accelerating growth currently being realized.
We are making incremental investments to ensure operational transformation projects are completed this year, creating a clear path for margin expansion in the second half and serving as a strong jumping off point for 2020.
Our fab Tech business is capturing expected price benefits. This year the business remains on track to deliver its profit plans with the benefits of cost and productivity projects offsetting flattish volume growth is now expected for the year.
Interest costs have been lowered to reflect the new rate environment, and we moved about $60 million to discontinued operations.
This $60 million represents interest expense savings from the $1.6 billion of approximate proceeds from the air and gas handling sale.
Because these proceeds will be used to repay borrowings related to the DJ Vu acquisition, the assumed interest savings or carry back to February 22nd.
We've updated the tax rate to 22% to 23%. The NCS headwind has been reduced to about $5 billion per year, and we are assuming approximately 137 million shares outstanding.
Adding all of this up we're targeting 190 to $2 per share of adjusted earnings for the year and 45% to 50 cents in the third quarter.
The more detailed pro forma pro forma view is included on slide 12.
The top chart walks from the original EPS guidance of 255% to 65 to the pro forma view of 190 to $2.
The key changes our inclusion of detail for a full year, rather than 10 months the sale of the air and gas handling business and finance costs and NC eyes savings as described a moment ago.
Also embedded in the finance cost number on the chart is $12 million for two additional months of interest costs for DJ show.
The continuing ops and pro forma guidance ranges are the same because the incremental EBITDA from DJ LOE for the first two months of the year is offset by the additional interest costs.
The Middle chart shows the pro forma EBITDA from selling the air and gas handling business and from getting a full year benefit from Djs, though the 590% to $610 million of forecasted pro forma EBITDA is 30% higher than our results before we started transforming our company in 2017 to be less cyclical faster growing higher margin and to generate cash more consistently.
The last chart on the page walks from the pro forma EBITDA free cash flow.
We're netting out one pro forma interest costs to expected cash taxes with a rate in the low twentys three restructuring costs unrelated to DJ those transformation projects that are expected to be completed this year.
For capital expenditures and five working capital use of cash unrelated to the $40 million of onetime investment in DJ show that was used to stabilize the supply chain and unwind inefficient factoring.
This $50 million to $60 million working capital drag on free cash flow includes items that we expect to wind down this year, including steel price pass throughs Bamtech acquisition integrations at a temporal or temporarily driven up working capital as facilities and functions our consolidated.
And elevated inventory to support DJ all operational transformation.
We've mapped out a path to significant reduction in working capital cash requirements in 2020, and expect free cash flow of $250 million or more next year and conversion from adjusted net income of 90% or more.
Concluding on slide 13, we're already seeing the benefits of the new Colfax.
The med Tech business is getting traction on operating improvements to support healthier growth and expected margin expansion.
Our fab Tech business continues to grow and to grow profitability to new levels.
Our company now has higher margins is less cyclical and we have an improved line of sight to hire more stable cash flow.
The Tamra, we'll take questions now from the colors.
Ladies and gentlemen, if you have a question at this time.
Please.
One.
Telephone keypad.
My question has been answered.
You mean, losing yourself from the queue. Please press the pound key.
The first response is from Jim Harmon of Keybanc capital. Please go ahead.
Hey, good morning, guys.
Good morning, Jeff.
So just on just to be clear on Med Tech margins just.
I mean, they seemed a little lower in the quarter, maybe you expected that.
What's kind of the guidance imply for second half for kind of an EBITDA margin run rate for further med tech margins through Q4.
Yes, the margins that we had for Medtech in the second quarter were consistent with what our view was for the when we when we set up our plans for the year, we we talked to in a previous call about more the Q1, having very high margins because it only included one five week month of the year of the quarter and that was March we described that second quarter margins would be lower than you'd see this improvement in margins in the back half of the year as we got more traction from the operating improvements and then you saw a sequential improvement in revenue in the fourth quarter.
So all of that is consistent with the original plans that we had and I think we laid out originally the expectation of M&A margins being in the 19% to 20% range on a 10 month basis, which would imply that we will be we will be in the high end of that or even slightly higher in the us in the third and fourth quarter.
Okay, that's great.
And then Fabtech very good resilience here.
Where do you think you're you're moving share or do you think it's just geographic mix and then.
Margins into the second half.
Maybe give us a sense of that.
Degree of margin improvement you get in that more flattish.
Volume environment I think you are up 90 basis points and you have an easy comp in the second half. Thanks.
Yes, Thanks, Jeff, Yes, I've said, a number of times through through the years, though we've got a strong team around the world in Fab Tech and and we built a great leadership team there and.
That that team has.
With strong service levels from from the plants has brought a lot of innovation in the marketplace. It's that's continuing through this year and as Don will have done a lot of work on improving the commercial process in the business using using CBS and and Thats paying off.
With some good good strong relative performance and share gain in that business and yet for sure part part of part of what we're getting there is some.
Some share gain in multiple places.
In the World certainly in Europe , and maybe a little bit in North America here recently.
But but also part of it is our healthy global footprint and our ability to.
Just a little too where the growth is over time, we think thats, a real real strength of the business and for sure that said, that's something that that is helping us on a relative growth basis as well.
As far as where the where the margins.
Going to the second half of the year.
I think.
The factors that are driving our margins up on a year over year basis are real improvements said that the teams made made to the business there and in terms of the hard work.
To to get the get the price through in the inflationary environment and get on the right side of that.
Ongoing productivity in the business as well as restructuring projects that we've been rolling through there.
Those are contributing to healthy margin expansion and we expect that healthy.
Margin expansion of more than 100 basis points to be able to continue through the back half of the year.
As I said in my comments Q3 is always a bit of a dip from from Q2 Q2 is always the healthiest, but but we do expect to stick with strong year over year margin expansion and and exit the year end in a place that is.
On the on track with that 15%.
LP.
Long term challenge that we put out there we think will exit this year within within sight of hitting that in the next year or two.
Okay, if I could sneak one in just on the interest expense can you just explain how you're coming up with that I think you said you're assuming.
You know the that you're taking the proceeds for a longer period of time or.
Just help me understand what the what the real run rate of interest expense going to be in the second half. Thanks.
Right.
Jeff the adjustments that we make is simply to take the 1.6 billion of proceeds and then back date that back to February 22nd and then apply the interest rate that we had through that period.
And then.
Attribute that to the discontinued ops. So it's a fairly straightforward calculation, there and thats what generated that roughly 60 million number for the full year that we have that we that we mentioned there.
And then I think in our we indicated the interest savings that are the interest costs that we would have on a pro forma basis is in that sort of $130 million to $135 million range as well now some of this there is some variability that just depending on the close date of the transaction. How soon we get the proceeds and and for what period of time, we continue to get the cash flow from the air and gas handling business.
Hi, Thanks, guys.
Thank you your next responses from Nathan Jones of Stifel. Please go ahead.
Good morning, everyone.
Hey, David.
Matt I'd, just like to start off.
Looking for a bit more detail on one of the comments you made about innovation you talked about the parts of the portfolio and I am This is Andy yes.
On that have you products showing good growth can you talk a little bit more about deposits that have maybe being a little neglected over the last couple of years that you're investing in what kinds of things you are doing there what the timeline is for getting those things to market just some details on that kind of stuff.
Yes, sure, yes first on the positive side of the comment.
There are parts of the business like surgical implants.
And like the French business as a different different example, more on the on the prevention and rehabilitation side, where the innovation investment has continued and there is strong above market.
Market growth that we've talked about surgical implants, but I think the French business is a great example, where there has been a lot of localized innovation by small team over there that that's kept the products fresh in that market and its remarkable how strong their performance has has been based on that freshness.
Yes, the areas of the portfolio that have had some gaps.
In the investment really are on that prevention and rehabilitation side.
Particularly in North America, but also affecting some some of the other countries.
Around the world and those are the areas that.
The team got debt you know turn the spigot back on.
Year or two ago, starting to put some.
Put some focus back on on investment in innovation in those those areas and some of those products are starting to come through this year and having some positive benefit on the business, but thats going to keep ramping in the back half of this year and into.
Into next year and beyond and that's really how we'll get the business up to sustainably above market growth rates on the prevention and rehabilitation side of the business.
Now that you've had.
The business here for first six odd months can you talk a little bit about.
Whether or not that the ramp up in innovation that is proceeding as you expected have you been able to accelerate it have you met with any problems in that.
I would say that it's it's fully fully on track I think we've been able to find more opportunities to build a pipeline around.
Then then we could see be before we acquired the business that we have a richer pipeline of ideas together today and the execution against those ideas is.
He is fully on track I think we were very clear with the team even in the time between sign and close that.
We wanted to support the focus that had been put back into innovation and even turn the dial up a little bit there and so I think things are things are coming through just fine in any company you got some product to come.
Exactly when you expected and some the take few more months to get to market and and we certainly got those those those kinds of dynamics and we see opportunities to improve the velocity of the innovation process and and the strength of the launch process with CBS and we're working with that on on the team but.
I think we see things as.
On track to continue to ramp the freshness of the business in a way that will contribute to better growth.
And then for my follow up I wanted to ask about one of the four areas you listed as a focus for CBS and the first year.
Prevention and rehabilitation supply chain pivot to continuous improvement can you talk about what kind of benefits. You think you can generate from supply chain is this just embedding CBS processes into a business that there was perhaps not as sophisticated in that area and any details you can give us on on the kinds of benefits do you think that you'll be able to generate from that.
Yes, sure Nathan I mean, so our first focus with the team that has been on getting the transformation project that it started.
Last year getting them through to the finish line and getting the supply chain fully stabilized and as as I talked about in my comments.
There has been really significant progress.
You know in this in the second quarter on that front with the.
Big drop in past dues and improvement in service levels and in some clear improvement in growth from that and positive feedback from the marketplace now thats been about transformation execution, but it's also being about.
Bring in CBS to bear in in helping I think Brady Brady it already put in place.
Some talent and an order changes early this year that are helping and then we brought some extra resourcing to bear as well as tools and we really made a lot of progress together there in in Q2.
The opportunity that we see really as we move to Q3 and beyond is to finish up those transformation projects, but then embed this ongoing continuous improvement culture and what that will enable is is to hold the high service levels, while over time getting inventory improvements and productivity improvements that support both the 50 basis points or better of margin improvement that we've talked about.
As well as some of the working capital improvements that Chris talked about in his comments.
Thanks, very much taking my questions.
Thank you your next responses from Joe Giordano from Cowen.
Hey, guys good morning.
Hi, Joe.
Hey.
Back on on fabrication internationally can you kind of talk I mean and margins, they're very good on no volume and we're talking about no volume probably for the back half of the year can you kind of maybe put a finer point on some of the.
Kind of the regional breakdowns on that margin and what are you guys and maybe some of the some of the specific things you're doing internally to kind of drive that one year.
So essentially just cost savings at this point right, yes, yes, I mean, our margin improvement.
Have been consistent across.
Most of the most of the business. So this is not.
Isolated to.
Two one region.
And.
We've said all along and we've been asked a lot of times, what it would take to get to the.
15%.
Oh P level or 16, and a half EBIT ebay I think we've consistently said that we could get most of the way there with.
Price productivity pricing productivity and restructuring efforts and then we'd need just a just a little bit of volume to get.
All the way there and so what you're seeing this year is strong improvements.
In in our margins with without the benefit of volume and we are confident that you can continue through the back half of the year and.
We do expect the industry should.
In the next year or so get back to some some volume growth and that should enable us to have a complimentary effect on margins were definitely focused on.
Making sure that we've got enough price productivity and restructuring lined up.
To make sure that that we can continue to expand the margins even in a flat volume environment.
On that point on the restructuring how do you. How are you guys thinking about restructuring across your enterprise now into second half and.
Into 2020 as well.
These on a comparative basis.
Yes, so first on Djs side, we've made some some very large structural restructuring if you're out of the gate. These transformation projects that were.
There were started before we acquired the business and so there is a.
Yes, a lot of restructuring dollars going into the finishing those projects and even leaning into the finished them as fast as possible and do them. The right way, that's going to pass and the level of detail restructuring as we roll into.
The second half of this year and in particular in into next year should go to kind of a very very low level.
On the on the Fab Tech side, we've had a combination this year of restructuring that's that's a normal structural work on on the organization.
And supply chain, but also a restructuring that's come on the back side of some of the acquisitions that we've made in capturing some of the some of the opportunities there and so we've been a bit of an elevated level. There in fab tech that that will continue through the back half of the year and as we look to next year, we're going to definitely be mindful of doing the right things to keep the business.
Getting leaner and expanding margins, but also being very conscious of the need to drive cash flow and cash conversion and so we'll be prioritizing the fabtech restructuring efforts to make sure that we're keeping the level of restructuring add at a manageable level related to our cash commitments and.
Conversion.
And maybe one last one for me just on the you mentioned a couple of times in the past due improvement and DJ. So I'm just curious as you look at your customer base, there and you know having history of past due and kind of supply chain issues before the acquisition can you talk about like impact on your customers and retention rates, there and how you've had to manage that situation.
Yes, so I mean, one of the things we liked about the industry is that there are strong brands that matter matter a lot, we confirm that DJ though as a very strong brand and even with some of the some of the challenges. The last few years still still had a very strong brand.
There is there is a channel that you're in a lot of parts of the business that is pretty pretty powerful as well in terms of being able to represent the leader in and and strengthen that position and there's these clinical position, where weve got work flow solutions that entrench us in the clinical workflow. So there were things that we like about this industry that we knew would enable stickiness.
And Thats the case here, yes, we had some.
A frustrated customers from the service level.
Interruptions and we missed some revenue for a number of quarters, there and lost a little bit of share here and there, but the vast majority of the customers and channels have ive stayed with the business and continued to give.
Feedback about.
Disappointment quarter or two ago and now feedback.
About.
Kind of positive feelings about where weve gotten to quickly together now.
Great. Thanks, guys.
Thank you. Your next response from Nicole Deblase Deutsche Bank.
Yeah. Thanks, good morning, guys cynical.
So I guess I want to start with free cash flow from a longer term perspective, I know you guys are saying, 90% plus kind of on a pro forma basis from here, but.
Is it possible to get to 100% plus conversion and that probably ties back to some of that working capital work that youre doing but I would love to hear a little bit of color there.
Sure Nicole the the I think we're really pleased to see the strong trajectory that we have right now going into 2020 that gets us into that 90% plus the 250 million or more of free cash flow and to your point the biggest.
Areas of that that we are managing our working capital and the restructuring as Matt mentioned, just a moment ago, we'll make sure that we are prioritizing that to ensure that we get the sort of cash flow delivery that we know the enterprise is capable of and at the same time manage working capital to be more efficient.
As we get into next year, we look to be 90% or more I think as you look longer down the road we have.
We have the opportunity to continue to drive that up the biggest variable I think longer term will just be the level of growth that we have in the enterprise and whether that growth is so strong and Medtech for example over overtime that it does require a little bit of investment of working capital.
So that that's our view.
Okay got it thanks and then.
For my follow up if we could just talk a little bit about stop tack on pricing, what's clearly still pretty strong this quarter on a decelerating from really really strong result in one Q. If you could talk a little bit about.
The price cost impact on margin this quarter and I guess how that trend.
As we move into the second half along with just like the absolute level of pricing.
Yes, sure we've continued to work hard to get price and we've got some some price cost benefit.
In the quarter now in fact, what we have had some.
Some reductions in the cost of steel some modest reductions in the cost of steel wheel theres. Some other inflation in the business.
On some of the other products that came through late last year and early this year and so we still have important reasons to keep holding holding price overtime and.
And again some of the price cost benefit that catches up from some of the.
Some of the.
The ramp up over the last year or so.
Going forward.
We certainly as.
As steel prices come down, which people do kind of expect that they should come down in the back half of this year and into next year for sure that will result in some downward pricing some of that is contractual and some of it is just the normal way the industry is as worked overtime, but.
Obviously, we'll be focusing on demonstrating the value to customers that enables us to keep up.
Keep improving our margins in the business and keep getting value based.
Price advantages in new products and applications, where we've got.
Kind of demonstrated differential value.
Thanks, I'll pass it on.
Thank you. Your next response from Andrew Kaplowitz. Please go ahead.
Good morning, guys.
Andrew Andrew.
Matt.
Can you talk about the cadence of orders you've been getting in fab Tech as you know many industrial companies have talked about a bit of a drop off in June but you did seem to mention relative stability. So is there anything that you're seeing sort of learning you in any of the particular regions you talked about the U.S. being little bit slower, but do you still think that volume growth there could be flattish for the rest of the year.
Yes, we definitely saw him in the end of the quarter.
Some some slowing in the U.S. and there's a lot of.
A lot of discussion with end users and with channel partners to to try to understand that.
And ultimately there's there's.
Some some views that the U.S. market has slowed down some and is in a little bit of a negative volume range and some views that there is some.
Some inventory trimming that that's been done that resulted in some of the negative volume in that that might pass.
In Q3 or as we move into Q4.
In the meantime, we've had.
Kind of.
A more positive volume picture in some other parts of the world Thats left us a little above flat and in the quarter.
And so our plan for the second half of the year is to plan on flat with us continuing to be down a little bit and some growth in some other parts of the world and to make sure that we're doing the right thing said to deliver our commitments in a in a flat volume growth environment.
That's helpful and then just.
Stepping back.
Can you give us some color on how you guys think about the cyclicality of DKL, obviously, it's not very cyclical, but would you expect to see some cyclicality prevention rehabilitation, if the us economy, Doug materially slow.
Yes. The analyses we have done on the past show that there is kind of a very limited impact on the business.
From from downturns it back in the 2009 to 2010 period. The business was it was flat or better so.
Our expectation is is that it is has a significant amount of insulation.
From from downturns based on that.
And then one quick one for Chris.
The guidance you gave on free cash flow for this year before you announce here in gas sale I think was $190 million to $210 million is it possible for sort of mark to market for us.
How does the current business looks versus that guidance I understand.
Improvement in 2020.
As as we mentioned in some of our prepared remarks, there we wanted to make sure that we clear 2019 with the DJ operational transformation projects completed so we're really leaning into that with the combination of Colfax resources and have been some additional investment. Our view is that we'll put we'll put an additional sort of 15 to 20 million into the restructuring this year to make sure that we clear it and then it doesn't to carry on into 2020, and so to Matt's point, we expect these sort of restructuring charges in DG ought to be very light next year as we as we cleared the projects make sure we've got the.
Operational tempo, where it needs to be and get our fair share of the customers will.
Appreciate it guys.
Thank you.
Im showing no further questions in the queue at this time.
I would like to turn the call back over to Mike Mike Salter.
Great. Thank you for joining us today, everyone. We look forward to updating you on our next call.
Ladies and gentlemen. This concludes today's conference. Thank you for your participation and have a great day you may all disconnect.